Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $2.25 billion. The enterprise value is $1.80 billion.
| Market Cap | 2.25B |
| Enterprise Value | 1.80B |
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 78.49 million shares outstanding. The number of shares has increased by 0.29% in one year.
| Current Share Class | 78.49M |
| Shares Outstanding | 78.49M |
| Shares Change (YoY) | +0.29% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 86.70% |
| Float | 72.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,597.04 |
| Forward PS | 626.73 |
| PB Ratio | 4.18 |
| P/TBV Ratio | 5.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,077.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.92, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.92 |
| Quick Ratio | 8.78 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.94% and return on invested capital (ROIC) is -33.17%.
| Return on Equity (ROE) | -48.94% |
| Return on Assets (ROA) | -30.89% |
| Return on Invested Capital (ROIC) | -33.17% |
| Return on Capital Employed (ROCE) | -67.22% |
| Weighted Average Cost of Capital (WACC) | 9.36% |
| Revenue Per Employee | $4,369 |
| Profits Per Employee | -$1.43M |
| Employee Count | 198 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.50% in the last 52 weeks. The beta is 0.93, so CLDX's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | +45.50% |
| 50-Day Moving Average | 32.06 |
| 200-Day Moving Average | 27.60 |
| Relative Strength Index (RSI) | 35.66 |
| Average Volume (20 Days) | 784,389 |
Short Selling Information
The latest short interest is 7.13 million, so 9.08% of the outstanding shares have been sold short.
| Short Interest | 7.13M |
| Short Previous Month | 7.60M |
| Short % of Shares Out | 9.08% |
| Short % of Float | 9.84% |
| Short Ratio (days to cover) | 9.10 |
Income Statement
In the last 12 months, CLDX had revenue of $865,000 and -$283.65 million in losses. Loss per share was -$4.27.
| Revenue | 865,000 |
| Gross Profit | -264.60M |
| Operating Income | -309.06M |
| Pretax Income | -283.65M |
| Net Income | -283.65M |
| EBITDA | -305.70M |
| EBIT | -309.06M |
| Loss Per Share | -$4.27 |
Balance Sheet
The company has $451.46 million in cash and $1.91 million in debt, with a net cash position of $449.55 million or $5.73 per share.
| Cash & Cash Equivalents | 451.46M |
| Total Debt | 1.91M |
| Net Cash | 449.55M |
| Net Cash Per Share | $5.73 |
| Equity (Book Value) | 456.23M |
| Book Value Per Share | 6.85 |
| Working Capital | 407.75M |
Cash Flow
In the last 12 months, operating cash flow was -$222.16 million and capital expenditures -$4.09 million, giving a free cash flow of -$226.25 million.
| Operating Cash Flow | -222.16M |
| Capital Expenditures | -4.09M |
| Depreciation & Amortization | 3.37M |
| Net Borrowing | n/a |
| Free Cash Flow | -226.25M |
| FCF Per Share | -$2.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | -35,729.83% |
| Pretax Margin | -32,791.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.29% |
| Shareholder Yield | -0.29% |
| Earnings Yield | -12.63% |
| FCF Yield | -10.07% |
Analyst Forecast
The average price target for CLDX is $58.43, which is 104.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $58.43 |
| Price Target Difference | 104.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 372.25% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 11.21 and a Piotroski F-Score of 1.
| Altman Z-Score | 11.21 |
| Piotroski F-Score | 1 |